Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Stuart J. Swiedler, Laila Arash et al.|The Journal of Pediatrics|2006Cited by 364
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Celeste Decker, Roberto Giugliani et al.|Molecular Genetics and Metabolism|2008Cited by 216
Multidisciplinary Management of Hunter SyndromeJoseph Muenzer, Ed Wraith, Michael Beck et al.|PEDIATRICS|2009Cited by 193
Biotinidase deficiency: Genotype-biochemical phenotype association in Brazilian patientsTaciane Borsatto, Ida Vanessa Döederlein Schwartz, Fernanda Sperb‐Ludwig et al.|PLoS ONE|2017Cited by 29